slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
213,991-214,020 of 319,975
13
The slide uses a matrix-like structure to map strategic initiatives against time and recurrence.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
14
Hyzon | Results Presentation Deck | 19 slidesHyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
15
The table includes both GAAP financial metrics and supplemental non-GAAP/operational data.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
16
The data shows a significant spike in legal/consulting/accounting fees in Q2 2023 due to SEC investigation accruals.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
17
The table includes footnotes explaining specific adjustments to the figures.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
18
Hyzon | Results Presentation Deck | 19 slidesHyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
19
The table includes adjustments for fair value changes, stock-based compensation, and legal/regulatory matters.Hyzon | Results Presentation Deck | 19 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
01
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
The slide highlights two distinct pipelines: TSTx (Tissue Specific Therapeutics) and NextGen CAR-T.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)1 hit
04
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and therapy type (CAR-T vs TSTx).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide uses a grouped bar chart to compare clinical outcomes across different patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
10
The slide uses a side-by-side comparison of two proprietary technology platforms.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
11
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
12
The slide uses a matrix structure to compare clinical outcomes against three key value propositions.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
13
Includes comparative bar charts and flow cytometry data.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
14
Includes a comparison table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
15
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
16
The slide compares two disease indications side-by-side with clinical metrics and competitive market context.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
The table uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
18
The chart demonstrates deepening clinical responses over time, a key indicator of therapeutic efficacy in oncology trials.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
19
The slide uses a red dashed box to highlight the key efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
20
The table displays clinical trial data for NXC-201, including toxicity management metrics like Tocilizumab and Dexamethasone usage.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
21
The slide highlights specific safety data points for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
22
The slide uses a structured table-like layout to map clinical progress against specific disease indications.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
23
The diagram illustrates a dose escalation process leading to the RP2D.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit